UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 197

Sortiert nach

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Link zum Volltext

Verfügbarkeit prüfen

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

European journal of cancer (1990), 2020-08, Vol.135, p.251-259

2020

Link zum Volltext

Verfügbarkeit prüfen

The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality

Frontiers in oncology, 2020-01, Vol.10, p.7-7

2020

Link zum Volltext

Verfügbarkeit prüfen

Benefit from adjuvant radiotherapy according to the number of risk factors in cutaneous squamous cell carcinoma

Radiotherapy and oncology, 2022-03, Vol.168, p.53-60

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in head and neck cancer: a new paradigm

Anti-cancer drugs, 2018-06, Vol.29 (5), p.385-386

2018

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab in recurrent/metastatic head and neck cancers

Future oncology (London, England), 2018-03, Vol.14 (7), p.603-609

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

BMC cancer, 2023-07, Vol.23 (1), p.663-663, Article 663

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

BMC cancer, 2011-02, Vol.11 (1), p.72-72, Article 72

2011

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for recurrent/metastatic head and neck cancers

Anti-cancer drugs, 2017-04, Vol.28 (4), p.357-361

2017

Link zum Volltext

Verfügbarkeit prüfen

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

Frontiers in oncology, 2021-02, Vol.11, p.614332-614332

2021

Link zum Volltext

Verfügbarkeit prüfen

Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18079-e18079

2019

Link zum Volltext

Verfügbarkeit prüfen

Induction chemotherapy in head and neck cancers: Results and controversies

Oral oncology, 2019-08, Vol.95, p.164-169

2019

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for localized head and neck squamous cell cancers

Anti-cancer drugs, 2017-04, Vol.28 (4), p.362-368

2017

Link zum Volltext

Verfügbarkeit prüfen

Survival of bronchopulmonary cancers according to radon exposure

Frontiers in public health, 2024-01, Vol.11, p.1306455-1306455

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas

Lung cancer (Amsterdam, Netherlands), 2016-12, Vol.102, p.42-43

2016

Link zum Volltext

Verfügbarkeit prüfen

Induction chemotherapy in head and neck cancer: a new paradigm

Anti-cancer drugs, 2011-08, Vol.22 (7), p.613-620

2011

Link zum Volltext

Verfügbarkeit prüfen

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN

ESMO open, 2020-12, Vol.5 (6), p.e001075-e001075, Article e001075

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(92)
Humans
(85)
Oncology
(82)
Female
(36)
Male
(34)
Middle Aged
(32)
Aged
(31)
Head And Neck Neoplasms - Drug Therapy
(28)
Life Sciences
(28)
Chemotherapy
(26)
Adult
(23)
Head And Neck Cancer
(23)
Immunotherapy
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Squamous Cell Carcinoma
(21)
Tumors
(19)
Cancer
(18)
Head & Neck Cancer
(18)
Retrospective Studies
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality

Benefit from adjuvant radiotherapy according to the number of risk factors in cutaneous squamous cell carcinoma

Immunotherapy in head and neck cancer: a new paradigm

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

Nivolumab in recurrent/metastatic head and neck cancers

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

Chemotherapy for recurrent/metastatic head and neck cancers

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice

Induction chemotherapy in head and neck cancers: Results and controversies

Chemotherapy for localized head and neck squamous cell cancers

Survival of bronchopulmonary cancers according to radon exposure

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors

Induction chemotherapy in head and neck cancer: a new paradigm

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN

Suchergebnisse filtern